Zobrazit v EDS

The volatile oil of Acorus tatarinowii schott significantly attenuates neuroinflammatory damage in a rat model of tourette syndrome by inhibiting the p38 MAPK/NLRP3/STAT3 signaling pathway.

Uloženo v:
Podrobná bibliografie
Název: The volatile oil of Acorus tatarinowii schott significantly attenuates neuroinflammatory damage in a rat model of tourette syndrome by inhibiting the p38 MAPK/NLRP3/STAT3 signaling pathway.
Autoři: Wei, Xing, Sun, Kexin, Feng, Peng, Huang, Shuang, Jiang, Bing, Cui, Min, Chen, Yuanhuan, Xue, Fuchun, He, Yuezhen, Yao, Jingxi, Shang, Jing, Mei, Hao, Ding, Yanqing, Tian, Yongyan, Guo, Guangyu, Yang, Nan, Shi, Zhenggang
Zdroj: Frontiers in Pharmacology; 2025, p1-24, 24p
Témata: TOURETTE syndrome, NEUROINFLAMMATION, ESSENTIAL oils, JAK-STAT pathway, NLRP3 protein, THERAPEUTICS, MITOGEN-activated protein kinases, CHINESE medicine
Abstrakt: Background: Acorus tatarinowii Schott holds a prominent position in Traditional Chinese Medicine, with its earliest record found in the ancient Chinese pharmacopeia, the Shennong's Classic of Materia Medica. It has been widely used for various central nervous system diseases. VOA has been shown to reduce neuroinflammation and repair neurons. However, the in vivo mechanisms by which this volatile oil alleviates neuroinflammation caused by Tourette syndrome remain unclear. Purpose: This study aims to investigate the effects and molecular mechanisms of VOA intervention in TS, providing scientific evidence for the potential therapeutic role of VOA in TS and paving the way for new treatment strategies. Methods: Forty-eight 3-week-old standard deviation rats were divided into a Blank group (n = 8) and a Model group (n = 40). After establishing the Tourette Syndrome animal model, the Model group rats were randomly divided into the Model, Tiapride, VOA, SB203580 and VOA + SB203580 groups. Following model induction, the respective treatments were administered continuously for 4 weeks. At the end of the intervention, Nissl staining was used to observe neuronal structure, and Enzyme-Linked Immunosorbent Assay, immunofluorescence, immunohistochemistry, RT-qPCR and WB were performed to determine the levels of inflammatory factors and protein expression. Results: Nissl staining showed that VOA significantly improved neuronal structure compared to the Model group. Compared to the Model group, the Tiapride, VOA, SB203580 and VOA + SB203580 groups had significantly reduced levels of TNF-α, IL-6, CD11b, COX-2, caspase-1, p38 MAPK, p-p38 MAPK, STAT3, p-STAT3, NLRP3, and GSDMD (P < 0.01 or P < 0.05) and significantly increased levels of IL-10 and CD163 (P < 0.01 or P < 0.05). Conclusion: VOA significantly alleviates neuroinflammation in TS rats by modulating the activity of the p38 MAPK/NLRP3/STAT3 signaling pathway, thereby improving the pathological characteristics of TS. These findings suggest that VOA could be a potential candidate for treating TS and other neuroinflammation-related diseases. [ABSTRACT FROM AUTHOR]
Copyright of Frontiers in Pharmacology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Databáze: Complementary Index
Popis
Abstrakt:Background: Acorus tatarinowii Schott holds a prominent position in Traditional Chinese Medicine, with its earliest record found in the ancient Chinese pharmacopeia, the Shennong's Classic of Materia Medica. It has been widely used for various central nervous system diseases. VOA has been shown to reduce neuroinflammation and repair neurons. However, the in vivo mechanisms by which this volatile oil alleviates neuroinflammation caused by Tourette syndrome remain unclear. Purpose: This study aims to investigate the effects and molecular mechanisms of VOA intervention in TS, providing scientific evidence for the potential therapeutic role of VOA in TS and paving the way for new treatment strategies. Methods: Forty-eight 3-week-old standard deviation rats were divided into a Blank group (n = 8) and a Model group (n = 40). After establishing the Tourette Syndrome animal model, the Model group rats were randomly divided into the Model, Tiapride, VOA, SB203580 and VOA + SB203580 groups. Following model induction, the respective treatments were administered continuously for 4 weeks. At the end of the intervention, Nissl staining was used to observe neuronal structure, and Enzyme-Linked Immunosorbent Assay, immunofluorescence, immunohistochemistry, RT-qPCR and WB were performed to determine the levels of inflammatory factors and protein expression. Results: Nissl staining showed that VOA significantly improved neuronal structure compared to the Model group. Compared to the Model group, the Tiapride, VOA, SB203580 and VOA + SB203580 groups had significantly reduced levels of TNF-α, IL-6, CD11b, COX-2, caspase-1, p38 MAPK, p-p38 MAPK, STAT3, p-STAT3, NLRP3, and GSDMD (P < 0.01 or P < 0.05) and significantly increased levels of IL-10 and CD163 (P < 0.01 or P < 0.05). Conclusion: VOA significantly alleviates neuroinflammation in TS rats by modulating the activity of the p38 MAPK/NLRP3/STAT3 signaling pathway, thereby improving the pathological characteristics of TS. These findings suggest that VOA could be a potential candidate for treating TS and other neuroinflammation-related diseases. [ABSTRACT FROM AUTHOR]
ISSN:16639812
DOI:10.3389/fphar.2025.1540092